ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Low Breast Carcinoma|Triple Negative Breast Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive Breast Carcinoma
Interventions: DRUG: ARX788|PROCEDURE: Computed Tomography (CT)|PROCEDURE: Biospecimen Collection
Sponsor: Laura Huppert, MD, BA
Collaborators: Ambrx, Inc.